LSTANasdaqPharmaceutical PreparationsFiscal year ends December 31

LISATA THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$1.00−0.03 (-2.91%)

Close on Oct 19, 2026

Market cap: $9.11M
P/E (TTM): –
Dividend yield: –

LISATA THERAPEUTICS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	0.17	1.00	0	0	–	–	–	–	–	35	22	18	15	14	10	70
Cost of Revenue	–	–	–	–	–	–	–	–	–	31	20	16	13	12	8.65	50
Gross Profit	–	–	–	–	–	–	–	–	–	4.15	2.33	2.26	1.72	2.38	1.40	20
Research & Development	7.95	11	13	13	18	9.25	11	7.59	16	17	24	29	17	10	7.72	7.68
Selling, General & Admin	–	–	13	14	11	9.89	9.30	9.39	12	13	30	31	22	22	28	31
General & Administrative	10	12	13	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Expenses	18	23	26	58	29	19	20	17	28	30	136	76	51	45	35	39
Operating Income	-18	-22	-26	-58	-29	-19	-20	-17	-28	-30	-114	-58	-37	-30	-34	-19
Interest Expense	–	–	–	–	–	–	0	0.01	0.38	1.78	2.13	0.76	0.28	1.58	2.65	0.48
Income from Equity Investments	0	-0.13	0	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	0.66	1.63	2.54	0.90	0.08	0.13	0.74	0.82	-0.11	-1.76	16	2.17	-1.90	-5.89	-0.56	0.03
Asset Impairment Charges	–	–	–	–	–	–	–	–	–	0	62	0	–	–	19	0.56
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.02
Gain (Loss) on Sale of Assets	–	0	0.00	0	–	–	0	1.43	-0.21	-0.59	0	0	0	-0.01	0	–
Pretax Income	-18	-21	-23	-57	-29	-19	-19	-16	-28	-31	-98	-56	-39	-36	-35	-19
Income Tax Expense	-0.96	-0.80	-2.33	-2.48	-1.51	-11	0	0	-12	0	-17	-0.10	0.78	-0.18	0	0.55
Income from Continuing Operations	–	–	–	–	–	–	–	-16	-16	-31	–	-55	-39	-36	-34	–
Income from Discontinued Operations	–	–	–	–	–	–	–	0	38	-2.05	–	0	0	-30	-22	–
Net Income incl. Noncontrolling Interests	-17	-20	-21	-54	-27	-8.14	-19	-16	22	-33	-81	-55	-39	-66	-57	-19
Minority Interest in Earnings	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-9.45	3.91
Net Income	-17	-20	-21	-54	-27	-8.15	-19	-16	23	-33	–	-55	-39	-54	-47	-23
Preferred Dividends	–	–	–	–	–	–	–	–	–	–	–	–	–	0.53	0.64	0.24
Net Income to Common	–	–	–	–	–	–	–	–	–	-33	-81	-55	-39	-55	-48	-24
EPS (Basic)(per share)	-1.91	-2.40	-2.58	-10.47	-7.45	-7.95	-28.20	-25.05	38.40	-74.85	-250.05	-252.00	-285.00	-600.00	-810.00	-690.00
EPS (Diluted)(per share)	-1.91	-2.40	-2.58	-10.47	-7.45	-7.95	-28.20	-25.05	38.40	-74.85	-250.05	-252.00	-285.00	-600.00	-810.00	-690.00
Shares Outstanding (Basic, Weighted)(shares)	8.69	8.33	8.07	5.18	3.69	1.03	0.69	0.65	0.60	0.44	–	–	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	8.69	8.33	8.07	5.18	3.69	1.03	0.69	0.65	0.60	0.44	–	–	–	–	–	–
EBITDA	-18	-22	-26	-58	-29	-19	-20	-17	-27	-29	-112	-56	-36	-29	-33	-14

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -16427.0%
Net margin: -14621.0%
Return on equity, FY2025: -74.7%

Financial strength

Current ratio: 3.69
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 349.6%

Valuation

P/E ratio: –
Price to sales: 91.06
Price to book: 1.10
Dividend yield: –